TLDR: MDR and IVDR converted device compliance from a launch project into a permanent operating function. That structural change, rather than a temporary backlog, is what keeps MedTech regulatory and quality hiring tight through 2026.
The European device regime turned compliance into permanent headcount rather than a launch project
Under the directives that governed European medical devices for two decades, regulatory work clustered around a launch. A manufacturer assembled a technical file, obtained a CE mark, and moved on to the next product with a modest maintenance burden behind it. The Medical Device Regulation and In Vitro Diagnostic Regulation dismantled that rhythm. Compliance now runs continuously across a product’s commercial life, and continuous obligations require standing teams rather than periodic project staffing.
Three mechanisms drive the change. Post-market surveillance became an active duty, with manufacturers expected to collect and analyse field data on a defined cycle and to feed conclusions back into clinical evaluation. Periodic safety update reporting created recurring deliverables for higher-risk classes. Post-market clinical follow-up turned the clinical evidence file into a living document that ages if nobody maintains it. Each of these produces work that arrives every year regardless of whether the company launches anything, and work with that shape cannot be covered by consultants brought in for a submission and released afterwards.
Reclassification widened the affected population considerably. The IVDR in particular moved diagnostics that manufacturers once self-certified under the old directive into classes requiring notified body involvement, which pulled companies that had never managed a notified body relationship into one for the first time. Many of those firms are small, and small firms feel a new permanent function most acutely because they lack the internal depth to absorb it. A diagnostics company of forty people that previously handled regulatory work through a part-time quality manager now needs a genuine regulatory capability, and it has to hire that capability from the same pool everyone else is drawing on.
The regulations also created a named individual whose absence blocks lawful operation. Manufacturers must designate a person responsible for regulatory compliance, who must hold a defined combination of formal qualification and documented regulatory experience, or a longer period of experience in place of the qualification. Smaller enterprises may appoint that person externally, provided they remain permanently and continuously available. A statutory role with statutory eligibility criteria converts an ordinary hiring preference into a hard constraint, and it explains why certain MedTech vacancies stay open at salaries that would fill an equivalent seat elsewhere in weeks.
Permanent obligations produce permanent demand, and that demand distributes unevenly across four distinct functions. Employers who treat regulatory affairs, quality, clinical evaluation and post-market surveillance as one interchangeable talent pool tend to hire the wrong profile and discover the mismatch during an audit, when correcting it is slowest and most expensive. The four behave differently, fail differently, and draw on different backgrounds. Getting the diagnosis right before writing a job specification is worth more than any amount of sourcing effort applied afterwards.
Four functions carry the workload, and each fails in a different way when it is understaffed
Understaffing in device compliance rarely announces itself as a missed deadline. It shows up as a notified body question that takes six weeks to answer, a clinical evaluation report that quietly stops reflecting the field data behind it, or a complaint trend that nobody has the hours to investigate properly. Reading the failure mode backwards is the most reliable way to work out which of the four functions a company is actually short of.
| Function | Core obligation it owns | Failure mode when understaffed | Backgrounds that transfer |
|---|---|---|---|
| Regulatory affairs (MedTech) | Classification, technical documentation, notified body dialogue | Certification timelines slip; questions go unanswered | Pharma regulatory, engineering, standards work |
| Quality assurance and QMS | ISO 13485 system, CAPA, supplier and design controls | Nonconformities accumulate; audit findings repeat | Aerospace, automotive, pharma quality |
| Clinical evaluation and clinical affairs | Clinical evidence, evaluation reports, post-market follow-up | Evidence ages out of line with the claims made | Clinical research, medical writing, biostatistics |
| Post-market surveillance and vigilance | Field data, complaints, trend analysis, incident reporting | Signals detected late; reporting clocks missed | Pharmacovigilance, quality data analysis |
Regulatory affairs sits closest to the certification clock, which makes it the most visible shortage and the most expensive one. A manufacturer waiting on a notified body has a finite window to respond to technical questions, and the quality of that response determines whether the review continues or restarts. Companies that staff this function thinly discover the cost at the worst moment, because the delay compounds: a slow answer pushes the file behind others in the queue, and queue position in a capacity-constrained system is worth more than any internal efficiency gain. This is precisely why experienced MedTech regulatory professionals command the premium they do.
Quality assurance carries the system the rest of the regime rests on. An ISO 13485 quality management system holds design controls, supplier controls, corrective and preventive action, and the traceability that lets a manufacturer answer questions about a device made three years ago. Quality talent transfers into MedTech from aerospace and automotive with unusual ease, because those sectors run the same discipline of controlled documents and evidenced decisions. What newcomers must absorb is the patient-facing risk framework and the specific expectations of device auditors, which is a matter of months rather than years for someone who already thinks in nonconformities.
Clinical evaluation and post-market surveillance sit at opposite ends of the same evidence loop, and shortages in either quietly undermine the other. Clinical evaluation establishes that a device performs as claimed and remains acceptable against the state of the art, a standard that moves as competing technologies improve. Post-market surveillance supplies the field data that keeps that assessment honest. When surveillance runs thin, evaluation reports get written against stale inputs; when evaluation runs thin, good field data goes unread. Manufacturers who hire only one side of this loop typically pay for the other during their next audit, at a higher price than the salary they avoided.
Diagnosing which function is short changes the hiring brief entirely, and it changes where the candidate should come from. It also changes how urgent the search is, because these four functions tolerate a vacancy very differently: a regulatory affairs gap during an active review costs money weekly, while a surveillance gap accumulates quietly until an authority asks a question nobody can answer. For manufacturers operating from Switzerland, all four of these questions arrive wrapped in an additional layer that companies inside the single market never have to think about at all.
Swiss manufacturers carry a double regulatory burden the single market does not impose
Switzerland’s position in the European device market changed when the mutual recognition agreement’s medical devices chapter stopped being updated to cover the new regulations. Swiss manufacturers lost the frictionless route into the EU that the agreement had provided, and they now operate under two regimes at once: Swissmedic and the Swiss Medical Devices Ordinance domestically, and the full EU regime for everything they export. That duplication has direct consequences for how Swiss MedTech companies staff their compliance function.
The practical machinery is the clearest illustration. A Swiss manufacturer selling into the EU needs an authorised representative established in the Union, with a mandate defining who holds which obligation. Manufacturers based outside Switzerland selling into the Swiss market need the mirror image, a Swiss authorised representative, along with Swiss labelling and importer arrangements. Each of these relationships has to be documented, maintained and defended when an authority asks. Somebody inside the company owns that work, and it is work that simply does not exist for a manufacturer headquartered in Germany or the Netherlands.
The consequence for hiring is a profile that is scarcer than either component alone. Swiss employers need people who can hold a Swissmedic conversation and an EU notified body conversation in the same week, understand where the two regimes align and where they diverge, and keep documentation that satisfies both without maintaining two parallel systems. That dual fluency is built through exposure rather than taught in a course, which limits supply structurally. It also travels well, which means the people who have it receive approaches regularly and know their market value with some precision.
Larger groups solve this with a European regulatory hub, often in Ireland, the Netherlands or Germany, and a smaller Swiss team focused on domestic obligations. Smaller Swiss manufacturers cannot split the function that way and must find the dual profile in one person, which puts them in direct competition with employers several times their size. Their advantage lies in scope: a compliance professional in a fifty-person Swiss diagnostics firm touches classification, clinical evaluation, surveillance and audits within a single year. Candidates weighing a move should treat that breadth as a genuine asset rather than a compromise.
The Swiss situation intensifies a shortage that already runs across Europe, and pressure of that kind rarely resolves on its own timetable. Employers frequently treat the tightness as a passing consequence of the transition, something that will ease once the backlog of certificates clears and the market settles. The evidence points the other way. Understanding why the scarcity holds — and why it will hold after every current deadline has passed — tells both employers and candidates precisely what to do with the next two years.
The shortage is structural, which rewards employers who develop this talent and candidates who commit to it
Market analysis of Swiss life sciences hiring places regulatory affairs among the roles employers find hardest to fill, and the reason sits in the arithmetic of experience rather than in any temporary imbalance. Competent MDR and IVDR practitioners are made by working through certification cycles, audit responses and surveillance rounds, because the judgement the work requires comes from having seen how a real reviewer reacts to a real file. Those cycles take years to complete. No amount of hiring urgency shortens them, which means the supply of qualified people expands at a pace set by the calendar rather than by the market.
This makes deliberate development the only reliable supply strategy for employers. A company that pairs an experienced regulatory lead with two capable people from adjacent disciplines — quality engineering, clinical research, pharmaceutical regulatory affairs — and gives them real ownership across a certification cycle produces practitioners in a defined timeframe. The alternative, waiting for a fully formed candidate to appear at an acceptable price, competes against every other employer running the same plan. The development route also retains better, because people who gained a scarce specialism inside a company that invested in them weigh an approach differently from people who simply arrived.
Candidates already inside MedTech should read the same arithmetic as a career instruction. Depth in this field appreciates rather than depreciates, because the obligations are permanent and the qualifying experience cannot be compressed. Choosing assignments that put a practitioner in front of a notified body, on an audit response, or inside a clinical evaluation build accumulates precisely the record employers cannot manufacture internally. Candidates arriving from pharma regulatory affairs, clinical research or industrial quality have a genuine on-ramp, provided they enter through a function that gives them ownership rather than support work.
Both sides benefit from realism about timing. The EU extended MDR and IVDR transition deadlines to relieve pressure on notified body capacity, and each extension moves the point at which demand peaks without reducing the total work in the system. Employers who read an extension as permission to defer a hire tend to compete for the same person twelve months later in a tighter market. Manufacturers who use the additional time to build capability convert a regulatory reprieve into a durable operating advantage.
The employers who come out of this period well will be the ones who staffed compliance as a permanent operating function rather than a recurring emergency. Edward Galle sources regulatory, quality, clinical and surveillance talent for MedTech and diagnostics employers across Switzerland, the EU and the United States. Companies can open a position with our team oder review how we run specialist search; candidates building an MDR or IVDR career can submit a CV for consideration.
References
- European Commission — Medical devices sector (MDR & IVDR). https://health.ec.europa.eu/medical-devices-sector_en
- Panda International. Swiss Life Sciences Hiring Trends for 2026. https://www.panda-int.com/en-ch/insights/swiss-life-sciences-hiring-trends-for-2026/
